- Evolus (EOLS, Financial) is set to launch Evolysse™ Form and Evolysse™ Smooth HA gels on April 18th, 2024.
- Jeuveau® has achieved over 14% US market share, aiding Evolus' strategy.
- Clinical trials indicate Evolysse™ products outperform Restylane®-L.
Evolus, Inc. (EOLS), a leader in performance beauty, has announced the commercial launch of its injectable hyaluronic acid (HA) gels, Evolysse™ Form and Evolysse™ Smooth, scheduled for April 18, 2024. This launch follows the success of Jeuveau®, which successfully captured over 14% of the U.S. market and entered more than 50% of aesthetic clinics.
The new Evolysse™ products leverage innovative Cold-X™ technology to treat facial wrinkles and folds with enhanced efficacy. In clinical trials, Evolysse™ Form and Evolysse™ Smooth demonstrated statistical superiority over Restylane®-L at the 6-month primary endpoint. Notably, Evolysse™ Smooth achieved significant results using 20% less product compared to its competitor.
To support the launch, Evolus has initiated an early experience program providing over 1,000 key accounts with access to the products, complemented by a national Evolus Academy webcast aimed at educating healthcare practitioners.
